


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 24 MAY 2019

The board of directors (the “Board”) of Dawnrays Pharmaceutical (Holdings) Ltd. (the “Company”) is pleased to announce that at the annual general meeting of the Company held on 24 May 2019 (the “AGM”), all the proposed resolutions as set out in the notice of annual general meeting of the Company dated 16 April 2019 (the “Notice of AGM”) were approved by shareholders by way of poll. Unless otherwise defined, capitalised terms used in this announcement have the same meanings as defined in the Notice of AGM.

As at the date of the AGM, the total number of issued shares of the Company was 1,586,382,000 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions at the AGM. There were no restrictions imposed on the shareholders of the Company casting votes on any resolutions proposed at the AGM. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and there were no shares requiring the holders to abstain from voting at the AGM under the Listing Rules. No parties have stated any intention in the circular of the Company dated 16 April 2019 that it would vote against or abstain from voting on any of the resolutions proposed at the AGM.

The Company’s branch share registrar and transfer office in Hong Kong, Tricor Abacus Limited, acted as the scrutineer for the vote-taking at the AGM.

The poll results are set out as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements and the reports of the directors and auditors for the financial year ended 31 December 2018.	1,214,345,872 (100.00%)	0 (0.00%)
2.	To declare a final dividend.	1,214,503,872 (100.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3.	(I) To re-elect Ms. LI Kei Ling as an executive director of the Company.	1,033,395,147 (85.09%)	181,108,725 (14.91%)
	(II) To re-elect Mr. EDE, Ronald Hao Xi as an independent non-executive director of the Company.	953,681,200 (78.52%)	260,822,672 (21.48%)
	(III) To re-elect Ms. LAM Ming Yee Joan as an independent non-executive director of the Company.	1,213,845,872 (99.95%)	658,000 (0.05%)
	(IV) To authorize the board of directors of the Company to fix the remuneration of the directors.	1,119,827,138 (100.00%)	0 (0.00%)
4.	To re-appoint Ernst & Young as Auditors of the Company and authorize the board of directors to fix their remuneration.	1,213,953,872 (99.95%)	550,000 (0.05%)
5.	Ordinary resolution no. 5 set out in the notice of the Annual General Meeting (to grant a general mandate to the directors of the Company to allot, issue and deal with new shares in the Company not exceeding 20% of the issued share capital of the Company).	971,756,473 (80.02%)	242,601,399 (19.98%)
6.	Ordinary resolution no. 6 set out in the notice of the Annual General Meeting (to grant a general mandate to the directors of the Company to repurchase shares in the Company not exceeding 10% of the issued share capital of the Company).	1,214,357,872 (100.00%)	0 (0.00%)
7.	Ordinary resolution no. 7 set out in the notice of the Annual General Meeting (to extend the general mandate to the directors of the Company to allot, issue and deal with new shares in the Company by an amount not exceeding the amount of shares in the Company repurchased by the Company).	972,476,653 (80.07%)	242,027,219 (19.93%)

As more than 50% of the votes were cast in favour of each of the Resolutions 1 to 7, all such resolutions were passed as ordinary resolutions.

Shareholders may refer to the Notice of AGM and the circular dated 16 April 2019 issued to shareholders for details of the above resolutions.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Ltd.
Pang Kit Ling
Company Secretary

Hong Kong, 24 May 2019

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

** for identification purpose only*